Morningstar

Verastem Doses First Patient in Pancreatic Cancer Trial

Provided by Dow Jones

By Dean Seal 




  Verastem Oncology said it has dosed its first patient in a trial of its investigational cancer medication as a treatment for KRAS G12D-mutated metastatic pancreatic cancer. 



  The biopharmaceutical company said Tuesday the Phase 2, open-label study will examine a 900 mg daily dose of its drug VS-7375 both as a monotherpay and in combination with cetuximab for patients with second-line metastatic pancreatic ductal carcinoma. 



  VS-7375 was previously granted the Food and Drug Administration's fast-track designation for KRAS G12D-mutated advanced or metastatic pancreatic cancer in both the first- and second-line treatment settings. 



  "We are focused on accelerating development of VS-7375 as quickly as possible across multiple tumor types where no approved treatments exist," said Michael Kauffman, president of development at Verastem. 





  Write to Dean Seal at dean.seal@wsj.com 





  (END) Dow Jones Newswires



  June 16, 2026 16:49 ET (20:49 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
4 Stocks to Buy Before They Rise Further
 
Plus, the member of the triple-digit club reporting earnings this week. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
The 10 Best Companies to Invest in Now
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
 
Russ Kinnel shares investment ideas from his annual Thrilling Funds list and discusses how he screens for quality investments in a sea of options. 
 
 
Russel Kinnel and Ivanna Hampton 
 
 
 
2 Undervalued Stocks to Buy Before They Rebound
 
These wide-moat stocks look attractive after their recent pullbacks. 
 
 
Susan Dziubinski 
 
 
 
The 10 Best Dividend Stocks
 
These are the top dividend-paying stocks to buy today. 
 
 
Susan Dziubinski 
 
 
 
 

			Sponsor Center